Trade Names:Capastat Sulfate- Powder for injection 1 g (as sulfate)/vial
Interferes with protein synthesis.
The T max is 1 to 2 h following IM administration.
Approximately 52% of capreomycin is excreted unchanged in the urine within 12 h.
Treatment of tuberculosis concomitantly with other antituberculous agents.
IV/IM 1 g/day (max, 20 mg/kg/day) for 60 to 120 days, followed by 1 g IV or IM 2 or 3 times weekly.
Store powder for injection at controlled room temperature (59° to 86°F). Reconstituted solution may be stored for up to 24 h in refrigerator (36° to 46°F).
May increase the risk of respiratory paralysis and renal function impairment.Nondepolarizing neuromuscular blocking agents (eg, tubocurarine)
Neuromuscular blockade may be enhanced.
None well documented.
Ototoxicity; hearing loss.
Leukocytosis; leukopenia; eosinophilia; thrombocytopenia.
Decreased bromosulfophthalein excretion; abnormal liver function tests.
Hypersensitivity (including febrile reactions, urticaria, maculopapular rash); pain; induration and excessive bleeding at injection site; sterile abscesses.
MonitorIM injection sites
Assess IM injection sites for pain, bleeding, induration, or evidence of abscess formation. Inform health care provider if noted and significant.Mycobacterial studies/Susceptibility tests
Assess mycobacterial studies and susceptibility tests before and periodically throughout therapy to detect possible resistance.
Safety and efficacy not established.
Dosage reduction is necessary.
Use with great caution in patients with preexisting renal insufficiency or auditory impairment.
May occur during therapy.
Renal injury with tubular necrosis, elevation of BUN or serum creatinine, and abnormal urinary sediment may occur.
May occur; perform audiometric measurements and assess vestibular function prior to therapy and at regular intervals during treatment.
Copyright © 2009 Wolters Kluwer Health.